Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | XBP1 | P17861 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | ACACB | O00763 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | RXRA | P19793 | 1/20 | 0.44 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL123415 | 0.86 | MAPT (0.55) | NPC1MAPTMEN1ALOX12KMT2A | |
| SCHEMBL15114294 | 0.84 | LMNA (0.57) | NPC1MAPTMEN1ALOX12KMT2A | |
| SCHEMBL27729574 | 0.83 | KMT2A (0.51) | NPC1MAPTMEN1ALOX12KMT2A | |
| SCHEMBL29034950 | 0.83 | ALDH1A1 (0.43) | NPC1MAPTKMT2ALMNAHPGD | |
| SCHEMBL18295408 | 0.83 | SLC6A4 (0.46) | MAPTLMNAHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL9721341 | 0.83 | LMNA (0.62) | MAPTMEN1KMT2ALMNAPOLB | |
| SCHEMBL14528314 | 0.83 | FFAR1 (0.50) | NPC1MAPTLMNAHPGDPOLB | |
| SCHEMBL4527180 | 0.83 | MAPT (0.50) | NPC1MAPTMEN1ALOX12KMT2A | |
| SCHEMBL13155583 | 0.83 | ACACB (0.53) | NPC1MAPTMEN1ALOX12KMT2A | |
| SCHEMBL7329813 | 0.82 | NQO1 (0.67) | NPC1MAPTMEN1ALOX12KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | ACADIA PHARMACEUTICALS INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2021249364-A1 | NOVEL ANALOGS OF PTEROSTILBENE AMINO ACID BEARING CARBONATES FOR TREATING A NON-ALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS | WANG, JINPING (CN) | 2021-12-16 | — | — | WO | disclosed |
| EP-3828170-A1 | METHOD FOR SAFELY PREPARING PIMAVANSERIN AND TARTRATE SALT THEREOF USING TRIPHOSGENE | Livzon New North River Pharmaceutical Co., Ltd. (CN) | 2021-06-02 | — | — | EP | disclosed |
| US-10968179-B2 | Charged ion channel blockers and methods for use | Nocion Therapeutics, Inc. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | Nocion Therapeutics, Inc. | 2020-09-17 | — | — | US | disclosed |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-09-05 | — | — | US | disclosed |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170166539-A1 | COMPOUND | AVEXXIN AS (NO) | 2017-06-15 | — | — | US | disclosed |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2016-09-15 | — | — | US | disclosed |
| WO-2013071039-A1 | MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS | ENSEMBLE THERAPEUTICS (US) | 2013-05-16 | — | — | WO | disclosed |
| US-8377639-B2 | Compounds for modulating RNA binding proteins and uses therefor | UNIVERSITY OF MASSACHUSETTS (US) | 2013-02-19 | — | — | US | disclosed |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-03-17 | — | — | US | disclosed |
| EP-0650476-B1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMA CO LTD (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-6136826-A | AMINOPIPERIDINE COMPOUNDS SUBSTITUTED WITH ALKANOYL | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2000-10-24 | — | — | US | disclosed |
| US-5760058-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5656642-A | Peripheral vasodilating agent containing piperidine derivative as active ingredient | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-08-12 | — | — | US | disclosed |
| US-5358949-A | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-25 | — | — | US | disclosed |
| WO-1994022826-A1 | PERIPHERAL VASODILATING AGENT CONTAINING N-ACYLATED 4-AMINO PIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1994-10-13 | — | — | WO | disclosed |
| EP-0236140-A2 | Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200290953-A1 | Charged Ion Channel Blockers and Methods for Use | TRPV1, TRPV2, TRPV5 | NPC1 399/4885MAPT 1799/4885MEN1 3082/4885 |
| US-20170166539-A1 | COMPOUND | CBR1, CBR3, CCR1 | NPC1 117/4885MAPT 4608/4885MEN1 2314/4885 |
| US-11840515-B2 | Methods for preparing N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and polymorphic form c | NR3C2, NR2C2, CYP4A22 | NPC1 1639/4885MAPT 4837/4885MEN1 4247/4885 |
| US-20160263083-A1 | ANTIBACTERIAL AGENTS: ARYL MYXOPYRONIN DERIVATIVES | POLRMT, POLR1C, FBL | NPC1 3918/4885MAPT 4817/4885MEN1 3377/4885 |
| US-20110065704-A1 | COMPOUNDS FOR MODULATING RNA BINDING PROTEINS AND USES THEREFOR | TIA1, ZFP3, RBM3 | NPC1 633/4885MAPT 4038/4885MEN1 1444/4885 |
| US-10968179-B2 | Charged ion channel blockers and methods for use | TRPV1, TRPV2, TRPV5 | NPC1 399/4885MAPT 1799/4885MEN1 3082/4885 |
| US-20170196862-A2 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885MAPT 4883/4885MEN1 4405/4885 |
| US-20190269683-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885MAPT 4883/4885MEN1 4405/4885 |
| US-10758534-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | NPC1 236/4885MAPT 4883/4885MEN1 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.